Study on High Dose IL-2 and Entinostat for Kidney Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a good performance status, meaning able to carry out daily activities without significant limitations.
• Expected to live more than 6 months.
• Have advanced kidney cancer that cannot be surgically removed, specifically clear cell type.
• Have measurable cancer that can be tracked using standard criteria.
• Allowed to have had up to two previous treatments for kidney cancer, including one with an immune checkpoint inhibitor.
• Must meet specific blood count and organ function requirements.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 90 days after.
• Men must agree to use contraception during the study and for 90 days after.
• Must have good lung and heart function, with no recent heart attacks or severe heart conditions.
• No history of stroke or brain metastases unless treated and stable for 6 months.

Exclusion Criteria

• Have previously received high dose IL-2 treatment.
• Currently taking valproic acid or medications affecting blood clotting, except for low-dose aspirin.
• Participating in another clinical trial or taking investigational drugs.
• Have an active infection requiring treatment.
• Pregnant or breastfeeding.
• Have had another cancer within the last 5 years, except for certain skin or localized cancers.
• Have uncontrolled medical conditions, such as severe heart disease, high blood pressure, or diabetes.
• Have HIV, unless well-controlled with medication.
• Have active hepatitis B or C infections.
• Have serious wounds or recent major surgery.
• Have a heart pumping ability below 45%.